BioMarin and n-Lorem partner to pursue first-in-disease ReNU syndrome ASO
Jul 27, 2026, 9:10 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The deal signals a meaningful expansion of BioMarin's pipeline into ultra-rare genetic diseases with a sizeable addressable patient base (75% of ReNU cases). While milestones are years away and success is not guaranteed, investors typically reward pipeline expansion and exclusive collaboration with potential future upside; risk remains due to early-stage nature and regulatory uncertainty.
AI summary
What happened, with direct paths to the underlying reporting
BioMarin and the n-Lorem Foundation unveiled a strategic collaboration and global exclusive license to develop a first-in-disease antisense oligonucleotide (ASO) for ReNU syndrome, caused by RNU4-2 variants. The program targets roughly 75% of ReNU cases and will advance from preclinical studies to lead-candidate selection, potentially expanding BioMarin's genetic medicines portfolio over the long term.
BioMarin and n-Lorem announce collaboration and global exclusive license for ReNU ASO.
Targeting RNU4-2 variant, estimated to be ~75% of ReNU cases.
ReNU discovered in 2024; no approved therapies address underlying cause.
Preclinical studies to lead-candidate selection; pathway to clinical trials planned.
Global ReNU population ~100,000; program could expand BioMarin's genetic medicines portfolio.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
BioMarin will acquire Alesta Therapeutics for $275 million upfront plus up to $215 million in milestones to obtain ALE1, an oral therapy for hypophosphatasia in Phase 1/2a. Alesta…
BioMarin Pharmaceutical's (BMRN) VOXZOGO study showed a 2.33 cm/year improvement in growth velocity, exceeding market expectations and securing plans for a supplemental New Drug A…
BioMarin Pharmaceutical reported that its experimental treatment for a rare genetic condition has met one of the primary goals in a late-stage study. This progress could enhance m…
BioMarin Pharmaceutical has discontinued mid-stage trials for a bone disorder treatment due to reports of hip joint dislocations, resulting in a 4% decline in share value. This de…
